Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 68001-646

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68001-646). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (546b07bd 7dba 49c9 8caf 7914600d4d19 01)

Chemical structure of divalproex sodium, showing the repeating unit of the sodium salt and its protonated form, illustrating the molecular composition related to the active ingredient in the drug.*

FDA Label Image

Image (546b07bd 7dba 49c9 8caf 7914600d4d19 02)

A line graph comparing the percentage reduction in CPS rate over a percentage of patients between Divalproex Sodium Delayed-Release Tablets and placebo. The y-axis shows percent change from -100% to 100%, indicating improvement or worsening. The x-axis shows the percent of patients from 0 to 100. The graph illustrates greater improvement for the Divalproex Sodium Delayed-Release Tablets group compared to the placebo group.*

FDA Label Image

Image (546b07bd 7dba 49c9 8caf 7914600d4d19 03)

A line graph depicting the percent reduction in CPS rate versus percent of patients for high and low dose divalproex sodium delayed-release tablets. The vertical axis shows improvement or worsening, while the horizontal axis shows percent of patients. Two lines represent high dose and low dose divalproex sodium delayed-release tablets' effects on CPS rate reduction.*

FDA Label Image

Image (546b07bd 7dba 49c9 8caf 7914600d4d19 04)

A bar graph comparing the effect of placebo versus divalproex sodium extended-release tablets. The y-axis represents a quantitative measure, ranging from 0 to 1.2. The bar for placebo is about 0.6, and the bar for divalproex sodium extended-release tablets reaches approximately 1.2, with a noted statistical significance (p=0.006).*

FDA Label Image

Label Divalproex Sodium Er Tablets Usp 250 mg 100 Counts (546b07bd 7dba 49c9 8caf 7914600d4d19 06)

Label for divalproex sodium extended-release tablets, USP 250 mg by BluePoint Laboratories. The film-coated tablets are oral, supplied in a package of 100 tablets. The label includes dosage form, strength, NDC number 68001-646-00, storage instructions, and manufacturer information for Unichem Laboratories Ltd. in India.*

FDA Label Image

Label Divalproex Sodium Er Tablets Usp 500 mg 100 Counts (546b07bd 7dba 49c9 8caf 7914600d4d19 07)

Label for divalproex sodium extended-release tablets, USP, 500 mg strength. The label indicates once-daily dosing, contains 100 tablets, and is manufactured by Unichem Laboratories Ltd. for BluePoint Laboratories. It advises dispensing the Medication Guide and includes storage instructions, warnings, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.